D-0419-2026 Class II Ongoing
FDA drug recall D-0419-2026 was initiated by Appco Pharma LLC on Mar 27, 2026 and is designated Class II. Reason for recall: cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. The recall status is ongoing. Affected quantity: 88,008 bottles- 100's count.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 8, 2026
- Initiation Date
- Mar 27, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 88,008 bottles- 100's count
Product description
Prazosin Hydrochloride Capsules, USP, 1mg, 100-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ, Manufactured by: Appco Pharma LLC, Piscataway, NJ, NDC 70377-066-11.
Reason for recall
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.
Distribution pattern
U.S.A. Nationwide
Code information
Lot:2404160C, Exp.:2026/MAR; 2406253C, Exp.:2026/MAY; 2407311C, Exp.: 2026/JUL; 2407312C, Exp.:2026/JUL; 2408350C, Exp.:2026/JUL; 2505172C, Exp.:2027/MAY; 2506191C, Exp.: 2027/JUN.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0419-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026